Mesoblast wins Japanese patent for stem cell platform
Mesoblast (ASX:MSB) has picked up a Japanese patent covering its Mesenchymal Precursor Cell (MPC) adult stem cell platform.
The patent grants Mesoblast exclusive commercial rights to all compositions of matter and uses of the platform in the Japanese market.
The protection, which applies regardless of the stem cell tissue source, will be valid through to September 2025.
Mesoblast also recently secured two Chinese patents covering its MPC platform - which also expire in 2029 - and an extension of its US composition-of-matter patents until March 2029.
The company is using its MPC platform to develop off-the-shelf regenerative medicine products. Lead targets include rheumatoid arthritis, congestive heart failure and orthopaedic conditions including spinal fusion.
The granting of the patent comes weeks after fellow Australian biotech BioDiem (ASX:BDM) won its own Japanese patent covering antimicrobial compound BDM-I.
Mesoblast shares were trading 0.16% lower at $6.15 as of around 1.30 pm on Wednesday.
Research project to produce fish-free omega-3
SCU researchers are investigating how to grow omega-3-producing microorganisms more cheaply...
Biodegradable smart patch can detect and treat blood clots
Researchers have developed a biodegradable smart patch that detects pressure changes and releases...
Biotech manufacturing facility opens in Brisbane
ENTRI, a purpose-built multimodal facility which will enable biotech companies to manufacture...
